Compare DNOW & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | DNLI |
|---|---|---|
| Founded | 1862 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.4B |
| IPO Year | 2014 | 2017 |
| Metric | DNOW | DNLI |
|---|---|---|
| Price | $15.72 | $18.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 20 |
| Target Price | $18.75 | ★ $35.75 |
| AVG Volume (30 Days) | ★ 2.1M | 1.7M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,648,000,000.00 | N/A |
| Revenue This Year | $79.69 | N/A |
| Revenue Next Year | $6.97 | $158.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $10.94 | $13.75 |
| 52 Week High | $17.26 | $27.30 |
| Indicator | DNOW | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 40.38 |
| Support Level | $15.14 | $18.07 |
| Resistance Level | $16.33 | $20.84 |
| Average True Range (ATR) | 0.57 | 0.81 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 57.02 | 43.07 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.